Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

pembrolizumab 45Paclitaxel 8Cisplatin 8Carboplatin 8lenvatinib 7Pemetrexed 5Gemcitabine 4camrelizumab 3Docetaxel 3Capecitabine 3epacadostat 2avelumab 2Fluorouracil 2Cetuximab 2Acetaminophen 2vicriviroc 1sinoporphyrin sodium 1penpulimab 1olaparib 1etoposide phosphate 1enzalutamide 1balstilimab 1apatinib 1Temozolomide 1Tadalafil 1Standard of Care 1Serotonin 5-HT3 Receptor Antagonists 1Radiotherapy 1Radiosurgery 1Poly(ADP-ribose) Polymerase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Immune Checkpoint Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡